Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04550234
Recruitment Status : Completed
First Posted : September 16, 2020
Last Update Posted : July 21, 2021
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female subjects. This study is intended to assess the relative bioavailability between the fixed dose combination (FDC, i.e. verinurad/allopurinol FDC capsule 12/300 mg) and free combination formulations of verinurad (i.e. verinurad prolonged release Hydroxypropyl methylcellulose [HPMC] capsule 12 mg) and allopurinol (i.e. allopurinol table 300 mg) in fasted and fed conditions. The study will also assess the relative bioavailability between a formulation only containing verinurad (i.e. verinurad prolonged release gelatin capsule 12 mg) and the FDC capsule.

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Drug: Verinurad prolonged release HPMC capsule Drug: Allopurinol Tablet Drug: Verinurad/Allopurinol FDC Capsule Drug: Verinurad prolonged release gelatin Capsule Phase 1

Detailed Description:

The study comprises of:

  • A Screening Period of maximum 28 days;
  • Five treatment periods during which subjects will be resident from the morning of Day -2 until at least 72 hours after dosing in Treatment Period 5; discharged on the morning of Day 4 of Treatment Period 5; and
  • A Follow-up Visit 7 to 14 days after the last dosing.

Each subject will receive 5 single dose treatments of verinurad and allopurinol or verinurad alone and subject will be involved in the study for 52 to 59 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised, Single Dose, 5-period, 5-treatment, Crossover Study to Assess the Relative Bioavailability of 4 Different Formulations of Verinurad and Allopurinol in Healthy Subjects
Actual Study Start Date : April 13, 2021
Actual Primary Completion Date : July 15, 2021
Actual Study Completion Date : July 15, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment 1
Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fasted state on Day 1.
Drug: Verinurad prolonged release HPMC capsule
Randomized subjects will receive oral dose of verinurad HPMC capsule.

Drug: Allopurinol Tablet
Randomized subjects will receive oral dose of allopurinol tablet.

Experimental: Treatment 2
Subjects will receive verinurad/allopurinol FDC capsule in fasted state on Day 1.
Drug: Verinurad/Allopurinol FDC Capsule
Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.

Experimental: Treatment 3
Subjects will receive verinurad/allopurinol FDC capsule in fed state on Day 1.
Drug: Verinurad/Allopurinol FDC Capsule
Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.

Experimental: Treatment 4
Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fed state on Day 1.
Drug: Verinurad prolonged release HPMC capsule
Randomized subjects will receive oral dose of verinurad HPMC capsule.

Drug: Allopurinol Tablet
Randomized subjects will receive oral dose of allopurinol tablet.

Experimental: Treatment 5
Subjects will receive verinurad prolonged release gelatin capsule in fasted state on Day 1.
Drug: Verinurad prolonged release gelatin Capsule
Randomized subjects will receive oral dose of Verinurad gelatin capsule.




Primary Outcome Measures :
  1. Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol (VAO) after dosing with verinurad/allopurinol FDC capsule and free combinations of verinurad and allupurinol (V/A) under fasted conditions by AUCinf [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and12 hours [h] post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose;Day 4: 72 h post-dose) ]
    Area under plasma concentration time curve from time zero to infinity (AUCinf) of verinurad, allopurinol and oxypurinol.

  2. Evaluation of the relative bioavailability of VAO after dosing with verinurad/allopurinol FDC capsule and free combinations of V/A under fasted conditions by AUClast [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast) of verinurad, allopurinol and oxypurinol.

  3. Evaluation of the relative bioavailability of VAO after dosing with verinurad/allopurinol FDC capsule and free combinations of V/A under fasted conditions by Cmax [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Maximum observed plasma (peak) drug concentration (Cmax) of verinurad, allopurinol and oxypurinol.


Secondary Outcome Measures :
  1. Evaluation of the relative bioavailability of VAO after dosing with with the verinurad/allopurinol FDC capsule and with free combinations of V/A under fed and fasted conditions by AUCinf [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Area under plasma concentration time curve from time zero to infinity of verinurad, allopurinol and oxypurinol.

  2. Evaluation of the relative bioavailability of VAO after dosing with with the verinurad/allopurinol FDC capsule and with free combinations of V/A under fed and fasted conditions by AUClast [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Area under the plasma concentration time curve from time zero to time of last quantifiable concentration of verinurad, allopurinol and oxypurinol.

  3. Evaluation of the relative bioavailability of VAO after dosing with with the verinurad/allopurinol FDC capsule and with free combinations of V/A under fed and fasted conditions by Cmax [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Maximum observed plasma (peak) drug concentration of verinurad, allopurinol and oxypurinol.

  4. Evaluation of the relative bioavailability of verinurad after dosing with the verinurad gelatin capsule and verinurad/allopurinol FDC capsule under fasted conditions by AUCinf [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Area under plasma concentration time curve from time zero to infinity of verinurad, allopurinol and oxypurinol.

  5. Evaluation of the relative bioavailability of verinurad after dosing with the verinurad gelatin capsule and verinurad/allopurinol FDC capsule under fasted conditions by AUClast [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Area under the plasma concentration time curve from time zero to time of last quantifiable concentration of verinurad, allopurinol and oxypurinol.

  6. Evaluation of the relative bioavailability of verinurad after dosing with the verinurad gelatin capsule and verinurad/allopurinol FDC capsule under fasted conditions by Cmax [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Maximum observed plasma (peak) drug concentration of verinurad, allopurinol and oxypurinol.

  7. Assessment of the pharmacokinetic (PK) profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by AUCinf [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Area under plasma concentration time curve from time zero to infinity of verinurad, allopurinol and oxypurinol.

  8. Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by AUClast [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Area under the plasma concentration time curve from time zero to time of last quantifiable concentration of verinurad, allopurinol and oxypurinol.

  9. Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by Cmax [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Maximum observed plasma (peak) drug concentration of verinurad, allopurinol and oxypurinol.

  10. Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by tmax [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Time to reach maximum observed plasma concentration following drug administration (tmax) of verinurad, allopurinol and oxypurinol.

  11. Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by tlag [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Time delay between drug administration and the first observed concentration in plasma (tlag) of verinurad, allopurinol and oxypurinol.

  12. Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by λz [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Terminal elimination rate constant (λz) of verinurad, allopurinol and oxypurinol.

  13. Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by t½λz [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t½λz) of verinurad, allopurinol and oxypurinol.

  14. Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by CL/F [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Apparent total body clearance of drug from plasms after extravascular administration (parent drug only) (CL/F) of verinurad, allopurinol and oxypurinol.

  15. Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by MRTinf [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRTinf) of verinurad, allopurinol and oxypurinol.

  16. Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by Vss/F [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Volume of distribution (apparent) at steady state following extravascular administration (Vss/F) of verinurad, allopurinol and oxypurinol.

  17. Assessment of the PK profiles of VAO when administered as verinurad/allopurinol FDC capsule,free combinations of V/A under fed and fasted conditions and of verinurad when administered as gelatin capsule under fasted conditions by Vz/F [ Time Frame: Days 1 to 4 (Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-dose; Day 4: 72 h post-dose) ]
    Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of verinurad, allopurinol and oxypurinol.

  18. Number of subjects with serious and non-serious adverse events [ Time Frame: From Screening (Days -28 to -2) to follow-up visit (7 to 14 days post final dose) ]
    Assessment of the safety of single doses of verinurad and allopurinol.

  19. Assessment of the pharmacodynamics (PD) of VAO when administered as verinurad/allopurinol FDC capsule and free combinations of V/A under fed and fasted conditions and of verinurad gelatin capsule under fasted conditions by observed values and percentage [ Time Frame: Day -1 (-24, -23, -22, -21, -20, -19, -18, -16, -14 and -12 h), Day 1 to 4 (Day 1: Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose Day 2: 24 h, Day 3: 48 h post-dose, Day 4: 72 h post-dose) ]
    Observed values and percentage change from baseline [CB] (time matched, Day -1) in serum uric acid [sUA] concentrations at each time point following administration of verinurad and allopurinol (verinurad only for Treatment 5) in each treatment period

  20. Assessment of the PD of VAO when administered as verinurad/allopurinol FDC capsule and free combinations of V/A under fed and fasted conditions and of verinurad gelatin capsule under fasted conditions by Emax, CB [ Time Frame: Day -1 (-24, -23, -22, -21, -20, -19, -18, -16, -14 and -12 h), Day 1 to 4 (Day 1: Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose Day 2: 24 h, Day 3: 48 h post-dose, Day 4: 72 h post-dose) ]
    Maximum percentage CB (time matched, Day -1) in sUA concentrations.

  21. Assessment of the PD of VAO when administered as verinurad/allopurinol FDC capsule and free combinations of V/A under fed and fasted conditions and of verinurad gelatin capsule under fasted conditions by tEmax, CB [ Time Frame: Day -1 (-24, -23, -22, -21, -20, -19, -18, -16, -14 and -12 h), Day 1 to 4 (Day 1: Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 and 12 h post-dose Day 2: 24 h, Day 3: 48 h post-dose, Day 4: 72 h post-dose) ]
    Time of maximum percentage CB (time-matched, Day -1) in sUA concentration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provision of signed and dated, written informed consent prior to any study specific procedures.
  • Healthy male and female subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture.
  • Have a body mass index between 18 and 30 kg/m^2 (inclusive) and weigh at least 50 kg and no more than 100 kg (inclusive).
  • Females must have a negative pregnancy test at screening and on admission to the unit and must be:

    1. not pregnant or currently lactating or breastfeeding.
    2. of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria: (i) postmenopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) levels in the postmenopausal range (FSH levels > 40 IU/mL).

      (ii) documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

    3. OR if of childbearing potential must be willing to use an acceptable method of contraception to avoid pregnancy for the entire study period.
  • Must be able to swallow multiple capsules and tablets.

Exclusion Criteria:

  • History of gout or any clinically significant disease which, in the opinion of the principal investigator (PI), may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
  • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of verinurad.
  • History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results as judged by the Investigator at screening and first admission, including:

    1. Alanine aminotransferase > 1.5 x upper limit of normal (ULN),
    2. Aspartate aminotransferase > 1.5 x ULN,
    3. Bilirubin (total) > 1.5 x ULN,
    4. Gamma glutamyl transpeptidase > 1.5 x ULN.
  • Any clinically significant abnormal findings in vital signs at the Screening Visit and/or admission to the Clinical Unit, including, but not limited to, any of the following:

    1. Pulse (resting, supine) < 50 beats per minute (bpm) or > 90 bpm,
    2. Systolic blood pressure (BP) < 90 mmHg or > 140 mmHg and/or diastolic BP < 50 mmHg or > 90 mmHg sustained for > 10 minutes while resting in a supine position.
  • Any clinically significant abnormalities on 12 lead electrocardiogram (ECG) at the Screening Visit, including, but not limited to any of the following:

    1. QTcF > 450 ms or < 340 ms or family history of long QT syndrome,
    2. Any significant arrhythmia
    3. Conduction abnormalities
    4. Clinically significant PR (PQ) interval prolongation (> 240 ms); intermittent second or third degree AV block, or AV dissociation
    5. Complete bundle branch block and/or QRS duration > 120 ms.
  • Any positive result at the Screening Visit for serum Hepatitis B surface antigen or Anti Hepatitis B core antibody, hepatitis virus C antibody, and human immunodeficiency virus antibody.
  • Suspicion or known Gilbert's and/or Lesch Nyhan syndrome.
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the PI.
  • Has received another new chemical or biological entity within 30 days or at least 5 half lives of the first administration of verinurad in this study.
  • Subjects who have previously received verinurad.
  • Plasma donation within 1 month of screening or any blood donation/loss of more than 500 mL during the 3 months prior to the Screening Visit.
  • Subjects who are pregnant, lactating or planning to become pregnant.
  • Hypersensitivity to verinurad, allopurinol or any drug with a similar chemical structure/class to verinurad and/or allopurinol.
  • Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the 3 months prior to screening.
  • Excessive intake of caffeine containing drinks or food as judged by the PI.
  • Positive screen for drugs of abuse or cotinine (nicotine) at the Screening Visit or positive screen for alcohol, drugs of abuse and cotinine on each admission to the study centre.
  • Use of drugs with enzyme inducing properties within 3 weeks prior to the first administration of verinurad.
  • Use of any prescribed or non prescribed medication including antacids, analgesics, herbal remedies, megadose vitamins and minerals during the 2 weeks prior to the first administration of verinurad or longer if the medication has a long half life.
  • Any AstraZeneca, Parexel or study site employee or their close relatives.
  • Subjects who cannot communicate reliably with the PI and/or is not able to read, speak and understand the German language.
  • Judgment by the PI that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  • Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  • Subjects with any special dietary restrictions such as subjects that are lactose intolerant or are vegetarians/vegans.
  • Subject is a carrier of the HLA B*58:01 allele.
  • Subject has a positive test result for severe acute respiratory syndrome corona virus (SARS-CoV-2) RT-PCR before randomisation.
  • Subject has clinical signs and symptoms consistent with Coronavirus disease 2019 (COVID-19), eg, fever, dry cough, dyspnoea, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission.
  • History of severe COVID-19 (hospitalisation, extracorporeal membrane oxygenation, mechanically ventilated).
  • Subjects who are regularly exposed to COVID-19 as part of their daily life.
  • Subjects who have had or are planning to have the COVID-19 vaccination within 4 weeks prior to screening or at any time during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04550234


Locations
Layout table for location information
Germany
Research Site
Berlin, Germany, 14050
Sponsors and Collaborators
AstraZeneca
Parexel
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT04550234    
Other Study ID Numbers: D5495C00014
First Posted: September 16, 2020    Key Record Dates
Last Update Posted: July 21, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the requests portal. All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
3-period
Crossover
URAT1 inhibitor
Xanthine oxidase inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Allopurinol
Verinurad
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Antioxidants
Protective Agents
Physiological Effects of Drugs